Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and PD-1 in Advanced Gastric Cancer
NCT03954756Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Henan Cancer Hospital. Primary endpoint: Overall survival rate at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03954756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954756.